Learning From the Immune System of Long-term Pancreatic Cancer Survivors

November is pancreatic cancer awareness month.

A look at the statistics from the SEER database is a stark reminder that pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent. Unfortunately, the last 30 years has not seen any significant improvement in survival for patients with this disease. Pancreatic cancer is projected to become the second leading cause of deaths due to cancer in the United States by 2030.

Read More

Advances in Pancreatic Cancer Research: Q&A With Christine Iacobuzio-Donahue, MD, PhD

This week, scientists from around the world will convene in Orlando, Florida, as the AACR hosts a conference titled Pancreatic Cancer: Advances in Science and Clinical Care. The conference will include discussion on the biological mechanisms of pancreatic cancer, drug development, epidemiology and risk factors, patient perspectives, and more.

Read More

New Nanotherapeutic Approved for Pancreatic Cancer

Yesterday, Onivyde, which is a nanotherapeutic form of the conventional chemotherapeutic irinotecan, was approved by the U.S. Food and Drug Administration (FDA) for use in combination with two other conventional chemotherapeutics, fluorouracil and leucovorin, to treat patients with advanced pancreatic cancer that has progressed despite treatment with gemcitabine-based chemotherapy.

Read More

On the Road to Better Pancreatic Cancer Treatments

Costas Lyssiotis, PhD, a 2013 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant recipient, is conducting research to understand the unique metabolism of pancreatic tumors and discover new therapeutic targets that can exploit the dependency of these tumors on the nutrients that fuel their growth.

Read More